Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Revenue
- Valuation
Upturn AI SWOT - About
LEGN 
Legend Biotech Corp (LEGN)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
08/28/2025: LEGN (1-star) is currently NOT-A-BUY. Pass it for now.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Number of Analysts
22 Analysts rated it
Well-followed company, solid analyst reports, reliable data for confident investing.
1 Year Target Price $77.27
1 Year Target Price $77.27
| 11 | Strong Buy |
| 10 | Buy |
| 1 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit -4.65% | Avg. Invested days 30 | Today’s Advisory PASS |
Upturn Star Rating | Upturn Advisory Performance  3.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 08/28/2025 |
Key Highlights
Company Size Mid-Cap Stock | Market Capitalization 6.34B USD | Price to earnings Ratio - | 1Y Target Price 77.27 |
Price to earnings Ratio - | 1Y Target Price 77.27 | ||
Volume (30-day avg) 22 | Beta 0.26 | 52 Weeks Range 27.34 - 59.62 | Updated Date 08/29/2025 |
52 Weeks Range 27.34 - 59.62 | Updated Date 08/29/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -1.78 |
Analyzing Revenue: Products, Geography and Growth
Revenue by Products
Product revenue - Year on Year
Revenue by Geography
Geography revenue - Year on Year
Earnings Date
Report Date 2025-08-11 | When - | Estimate -0.12 | Actual 0.03 |
Profitability
Profit Margin -40.83% | Operating Margin (TTM) -8.58% |
Management Effectiveness
Return on Assets (TTM) -7.81% | Return on Equity (TTM) -29.65% |
Valuation
Trailing PE - | Forward PE 1000 | Enterprise Value 5828651860 | Price to Sales(TTM) 7.96 |
Enterprise Value 5828651860 | Price to Sales(TTM) 7.96 | ||
Enterprise Value to Revenue 7.31 | Enterprise Value to EBITDA -15.34 | Shares Outstanding 184571008 | Shares Floating 162765522 |
Shares Outstanding 184571008 | Shares Floating 162765522 | ||
Percent Insiders 1.3 | Percent Institutions 47.33 |
Upturn AI SWOT
Legend Biotech Corp
Company Overview
History and Background
Legend Biotech Corp. was founded in 2014. It is a global biotechnology company dedicated to discovering, developing, manufacturing and commercializing novel cell therapies for oncology and other indications.
Core Business Areas
- Cell Therapy Development: Focused on developing and commercializing innovative cell therapies, particularly in the CAR-T field, for the treatment of hematologic malignancies and solid tumors.
- Manufacturing: Establishing and scaling up manufacturing capabilities to support clinical trials and commercial supply of their cell therapy products.
- Research and Development: Conducting preclinical and clinical research to identify and develop new cell therapy targets and technologies.
Leadership and Structure
Legend Biotech is led by a management team with experience in biotechnology and pharmaceuticals. The organizational structure includes research, development, manufacturing, and commercial operations divisions.
Top Products and Market Share
Key Offerings
- Carvykti (ciltacabtagene autoleucel): A CAR-T cell therapy approved for the treatment of relapsed or refractory multiple myeloma. Market share data is dynamic and dependent on competitive landscape and evolving adoption. Competitors include Bristol Myers Squibb (Abecma) and Johnson & Johnson (Tecvayli). Revenue generated is significant and growing with increased use.
Market Dynamics
Industry Overview
The cell therapy market is rapidly growing, driven by advancements in immunotherapy and the potential for personalized medicine. The industry is highly competitive, with numerous companies developing CAR-T and other cell-based therapies.
Positioning
Legend Biotech is a key player in the CAR-T therapy market, focusing on developing and commercializing innovative treatments for hematologic malignancies. Their competitive advantages include established expertise and partnerships.
Total Addressable Market (TAM)
The TAM for cell therapies in oncology is projected to reach billions of dollars. Legend Biotech, with Carvykti, is well-positioned to capture a significant portion of this market.
Upturn SWOT Analysis
Strengths
- Approved CAR-T therapy (Carvykti)
- Strong manufacturing capabilities
- Strategic partnership with Janssen
- Innovative research and development pipeline
Weaknesses
- Reliance on a single approved product
- High cost of goods sold for cell therapies
- Competition in the CAR-T market
- Dependence on collaboration agreements
Opportunities
- Expansion into new indications for Carvykti
- Development of next-generation CAR-T therapies
- Geographic expansion into new markets
- Strategic acquisitions and collaborations
Threats
- Regulatory hurdles and delays
- Reimbursement challenges
- Adverse events associated with CAR-T therapy
- Emergence of novel therapies from competitors
Competitors and Market Share
Key Competitors
- BMY
- JNJ
Competitive Landscape
Legend Biotech benefits from early CARVYKTI approval. Competition hinges on efficacy, safety profiles, pricing, and market access. Continued innovation will be critical.
Growth Trajectory and Initiatives
Historical Growth: Legend Biotech has experienced significant growth in recent years, driven by the approval and commercialization of Carvykti.
Future Projections: Future growth is expected to be driven by continued adoption of Carvykti, expansion into new indications, and development of new therapies.
Recent Initiatives: Recent initiatives include expanding manufacturing capacity, conducting clinical trials in new indications, and seeking regulatory approvals in new markets.
Summary
Legend Biotech is a prominent player in the CAR-T therapy market, strengthened by Carvykti. High manufacturing costs and competition pose challenges, but strategic partnerships and pipeline diversification provide growth opportunities. Continued expansion is needed to secure market leadership. Monitoring evolving regulatory and competitive landscapes is crucial.
Peer Comparison
Sources and Disclaimers
Data Sources:
- Company filings, Press releases, Analyst reports, Market Research Reports
Disclaimers:
This analysis is based on publicly available information and analyst estimates. Actual results may vary. This is not financial advice.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Legend Biotech Corp
Exchange NASDAQ | Headquaters Somerset, NJ, United States | ||
IPO Launch date 2020-06-05 | CEO & Director Dr. Ying Huang Ph.D. | ||
Sector Healthcare | Industry Biotechnology | Full time employees 2800 | Website https://www.legendbiotech.com |
Full time employees 2800 | Website https://www.legendbiotech.com | ||
Legend Biotech Corporation, through its subsidiaries, operates as a biopharmaceutical company that discovers, develops, manufactures, and commercializes novel cell therapies for oncology and other indications in the United States, China, and Europe. Its lead product candidate is ciltacabtagene autoleucel, or cilta-cel, which is a chimeric antigen receptor (CAR-T) therapy for the treatment of multiple myeloma (MM). The company also has a portfolio of earlier-stage autologous CAR-T product candidates targeting various cancers, including Non-Hodgkins Lymphoma (NHL), acute lymphoblastic leukemia, gastric cancer, esophageal cancer, pancreatic cancer, colorectal cancer, hepatocellular carcinoma, small cell lung cancer, and non-small cell lung cancer. In addition, it develops allogeneic gamma delta CAR-T and allogeneic CAR-NK product candidates targeting B-cell maturation antigen (BCMA) for MM, which are in investigator-initiated Phase 1 clinical trials in China. The company has a collaboration and license agreement with Janssen Biotech, Inc. for the development and commercialization of cilta-cel, as well as a license agreement with Novartis Pharma AG for the development, manufacture, and commercialization of CAR-T cell therapies targeting delta-like ligand protein 3. The company was founded in 2014 and is headquartered in Somerset, New Jersey.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.